Jasper Van Beek

Mr. Jasper Van Beek

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2014 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
NHNiek Hugen
Niek Hugen
JBJasper Van Beek
Jasper Van Beek
JWJohannes H. W. de Wilt
Johannes H. W. de Wilt
INIris D. Nagtegaal
Iris D. Nagtegaal

15 August 2015 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
ASAnnette E Sköld
Annette E Sköld
JBJasper Van Beek
Jasper Van Beek
SSSimone P Sittig
Simone P Sittig
GBGhaith Bakdash
Ghaith Bakdash
JTJurjen Tel
Jurjen Tel
IVI. Jolanda M. De Vries
I. Jolanda M. De Vries
Dendritic cells (DCs) are key in connecting innate and adaptive immunity. Their potential in inducing specific immune responses has made them interesting targets for immunotherapeutic approaches. Our research group was the first to exploit the naturally occurring myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) in therapeutic vaccination trials against melanoma. To develop primary DC subsets as an optimal vaccine, the identification of a clinically applicable adjuvant activating both subsets is required. Although the expression of pathogen recognition receptors differs distinctly between the DC subsets, both pDCs and mDCs can respond to single-stranded RNA (ssRNA) via Toll-like receptors 7 and 8, respectively. Since ssRNA is easily degraded by RNases, we stabilized anionic RNA by complexing it with the positively charged protein protamine. This leads to the formation of protamine–RNA complexes with varying features depending on ionic content. We subsequently investigated the immunostimulatory effect of complexes that formed various salt concentrations on purified DC subsets. Both mDCs and pDCs upregulated maturation markers and produced pro-inflammatory cytokines in a dose-dependent way to the protamine–RNA complexes. This was dependent on endosomal acidification and correlated partly with the uptake of protamine–RNA complexes. Furthermore, both DC subsets induced T cell proliferation and IFN gamma secretion in a beneficial ratio to IL-10. These results indicate that protamine–RNA complexes can be used to stimulate human mDC and pDC ex vivo for use in immunotherapeutic settings.

1 January 2014 in Critical Reviews in Immunology
Verified
Journal Article
Closed access
PDF file
JBJasper Van Beek
Jasper Van Beek
FWFlorian Wimmers
Florian Wimmers
SHStanleyson V. Hato
Stanleyson V. Hato
IVI. Jolanda M. De Vries
I. Jolanda M. De Vries
ASAnnette E. Skold
Annette E. Skold
Dendritic cells (DCs) are key players in the induction of immune responses. Adoptive transfer of autologous mature DCs loaded with tumor-associated antigens is a promising therapy for the treatment of immunogenic tumors. For a long time, its therapeutic activity was thought to depend solely on the induction of tumor-specific CD8+ and CD4+ T cell responses. More recently, DCs were shown to bidirectionally interact with innate and innate-like immune cells, including natural killer (NK), invariant natural killer T (iNKT), and γδ T cells. These effector cells can amplify responses induced by DCs via several mechanisms, including induction of DC maturation and conventional T cell priming. In addition, NK, iNKT, and γδ T cells possess cytolytic activity and can act directly on tumor cells. Therapeutic strategies targeting these innate and innate-like immune cells hence hold potential to improve current DC vaccination protocols.

6 March 2021 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
SSSimone P. Sittig
Simone P. Sittig
JBJasper Van Beek
Jasper Van Beek
GFGeorgina Flórez‐Grau
Georgina Flórez‐Grau
JWJorieke Weiden
Jorieke Weiden
SBSonja I. Buschow
Sonja I. Buschow
GSGerty Schreibelt
Gerty Schreibelt
Dendritic cells (DCs) are key regulators of the immune system that shape T cell responses. Regulation of T cell induction by DCs may occur via the intracellular enzyme indoleamine 2,3‐dioxygenase 1 (IDO), which catalyzes conversion of the essential amino acid tryptophan into kynurenine. Here, we examined the role of IDO in human peripheral blood plasmacytoid DCs (pDCs), and type 1 and type 2 conventional DCs (cDC1s and cDC2s). Our data demonstrate that under homeostatic conditions, IDO is selectively expressed by cDC1s. IFN‐γ or TLR ligation further increases IDO expression in cDC1s and induces modest expression of the enzyme in cDC2s, but not pDCs. IDO expressed by conventional DCs is functionally active as measured by kynurenine production. Furthermore, IDO activity in TLR‐stimulated cDC1s and cDC2s inhibits T cell proliferation in settings were DC‐T cell cell‐cell contact does not play a role. Selective inhibition of IDO1 with epacadostat, an inhibitor currently tested in clinical trials, rescued T cell proliferation without affecting DC maturation status or their ability to cross‐present soluble antigen. Our findings provide new insights into the functional specialization of human blood DC subsets and suggest a possible synergistic enhancement of therapeutic efficacy by combining DC‐based cancer vaccines with IDO inhibition.

2 September 2016 in OncoImmunology
Verified
Journal Article
Open access
JBJasper Van Beek
Jasper Van Beek
MGMark A.J. Gorris
Mark A.J. Gorris
ASAnnette E. Sköld
Annette E. Sköld
IHIbrahim Hatipoglu
Ibrahim Hatipoglu
HAHeleen H. Van Acker
Heleen H. Van Acker
GBGhaith Bakdash
Ghaith Bakdash
Human blood dendritic cells (DCs) hold great potential for use in anticancer immunotherapies. CD1c+ myeloid DCs and plasmacytoid DCs (pDCs) have been successfully utilized in clinical vaccination trials against melanoma. We hypothesize that combining both DC subsets in a single vaccine can further improve vaccine efficacy. Here, we have determined the potential synergy between the two subsets in vitro on the level of maturation, cytokine expression, and effector cell induction. Toll-like receptor (TLR) stimulation of CD1c+ DCs induced cross-activation of immature pDCs and vice versa. When both subsets were stimulated together using TLR agonists, CD86 expression on pDCs was increased and higher levels of interferon (IFN)-α were produced by DC co-cultures. Although the two subsets did not display any synergistic effect on naive CD4+ and CD8+ T cell polarization, CD1c+ DCs and pDCs were able to complement each other's induction of other immune effector cells. The mere presence of pDCs in DC co-cultures promoted plasma cell differentiation from activated autologous B cells. Similarly, CD1c+ DCs, alone or in co-cultures, induced high levels of IFN-γ from allogeneic peripheral blood lymphocytes or activated autologous natural killer (NK) cells. Both CD1c+ DCs and pDCs could enhance NK cell cytotoxicity, and interestingly DC co-cultures further enhanced NK cell-mediated killing of an NK-resistant tumor cell line. These results indicate that co-application of human blood DC subsets could render DC-based anticancer vaccines more efficacious.

25 February 2016 in Biomedicines
Verified
Journal Article
Open access
PDF file
JBJasper Van Beek
Jasper Van Beek
AMAnne W. J. Martens
Anne W. J. Martens
GBGhaith Bakdash
Ghaith Bakdash
IVI. Jolanda M. De Vries
I. Jolanda M. De Vries
Innate lymphoid cells (ILCs) are a group of immune cells of the lymphoid lineage that do not possess antigen specificity. The group includes natural killer (NK) cells, lymphoid tissue inducer (LTi) cells and the recently identified ILC1s, ILC2s and ILC3s. Although the role of NK cells in the context of cancer has been well established, the involvement of other ILC subsets in cancer progression and resistance is just emerging. Here, we review the literature on the role of the different ILC subsets in tumor immunity and discuss its implications for cancer treatment and monitoring.